Order byBest matchMost fresh
23andMe to Be Bought by Biotech Company for $256 Million
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer consumer DNA testing services.
Regeneron Pharmaceuticals to buy 23andMe for $256M
Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March following a series of setbacks.
MassDevice40m
Regeneron to acquire 23andMe for $256M, plans to continue consumer genetics services
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to close in Q3 2025
23andMe Sold To Biotechnology Company For $256 Million
The acquisition comes two months after the genetic testing company filed for Chapter 11 bankruptcy protection.
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.
Explore more
23andMe sale grafts a happy ending on to a glum tale
Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue
Timeline: 23andMe’s Journey From DNA Testing Pioneer to Bankruptcy Sale
What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.
Feedback